Search

The aim of this study is to determine the accuracy rate of bronchopulmonary dysplasia (BPD) diagnosis and risk factors of short-term poor prognosis for premature infants. This study analyzed the clinical data of 81 premature infants (<32 weeks gestational age) with BPD, who were on oxygen therapy >28 days, and survived >36 weeks (corrected age). Outcome measures included treatments, conditions on the 28th day after birth, oxygen therapy conditions at the 36th week, occurrence of any serious complications during hospital stay. The major risk factors affecting prognosis were ventilation duration, duration of oxygen therapy, application of steroids, hypothyroidism and severity of BPD (all P<0.05). Interventions for complications (n=53) resulted in ceased inhalation of oxygen in 12 infants, improvement of symptoms in 26 infants, and were ineffective in 15 infants. BPD prognosis can be improved by shortening the duration of invasive ventilation and correcting thyroid function. [ABSTRACT FROM AUTHOR]

Objective The objective of this study was to determine the association between hemoglobin (Hb) levels in the first 3 days of life and bronchopulmonary dysplasia (BPD) in preterm infants. Study Design The study population comprises 147 neonates with a gestational age (GA) of less than 32 weeks who were admitted to BaYi Children's Hospital Affiliated to Beijing Military General Hospital from January 2014 to May 2015. Hb levels in the first 3 days of life, maternal and infant characteristics, were recorded and then analyzed. Results BPD patients had a lower GA and birth weight than non-BPD patients. Rates of surfactant use, use of early inhalation hormone, days of mechanical ventilation > 2 weeks, and patent ductus arteriosus in BPD patients were higher and have a significant difference. Number of transfusions was higher in BPD patients. Lower Hb levels in the first 3 days of life were also observed in BPD patients. A cutoff value of Hb levels was determined as 155.5 g/L. Hb ≤ 155 g/L in the first 3 days of life was a significant risk factor for BPD. Conclusion Our study demonstrated that lower Hb levels in the first 3 days of life may increase the risk of developing BPD in preterm infants. [ABSTRACT FROM AUTHOR]

Background: No evidence exists on the impact of bivalirudin in patients with the acute coronary syndrome undergoing rotational atherectomy. This study aimed to evaluate the impact of bivalirudin on patients with acute coronary syndrome undergoing rotational atherectomy. Methods: This was a retrospective cohort study conducted in our hospital between January 2017 and December 2019. The study included patients with acute coronary syndrome undergoing rotational atherectomy. Furthermore, 2 cohorts were included in this study (bivalirudin cohort and control cohort unfractionated heparin). The primary endpoint was in-hospital net adverse clinical events. The secondary endpoint was all-cause mortality at 23 months. Results: The study included 157 patients with 33 (21.0%) in the bivalirudin cohort and 124 (79.0%) in the control cohort. Net adverse clinical events during hospitalization in the bivalirudin cohort were higher than that in the control cohort [9 (27.3%) vs. 14 (11.3%), P = .021]. However, there was no significant difference in all-cause mortality at 23 months between the 2 cohorts [25 (20.2%) vs. 10 (30.3%), P = .214]. After adjusting for potential confounders, the usage of bivalirudin was not associated with net adverse clinical event (odds ratio = 0.90; 95% CI: 0.18-4.45; P = .890), and the hazard ratio for all-cause mortality at 23 months was 1.01 (95% CI: 0.33-3.15; P = .983). Conclusion: Bivalirudin appears to exhibit a similar impact as unfractionated heparin on patients with acute coronary syndrome undergoing rotational atherectomy in real-life setting. [ABSTRACT FROM AUTHOR]

Background/aim: To investigate the effects of keratinocyte growth factor (KGF) on the growth and transdifferentiation of primary alveolar epithelial type II cells (AECIIs). Materials and methods: The number of primary AECIIs, their viability, and cell cycle and apoptosis were studied under KGF treatment using a hemocytometer, trypan blue exclusion, and flow cytometry, respectively. Positive expressions of surfactant protein C (SP-C), aquaporin 5 (AQP5), and thyroid transcription factor 1(TTF-1) were examined with indirect immunofluorescence; mRNA levels of SPC, AQP5, and TTF-1 were determined by polymerase chain reaction. Results: In response to KGF treatment, cell numbers were significantly increased, more cells were blocked in the S phase, and fewer cells were apoptotic or necrotic on days 2 and 4, but there was little effect on cell viability. In addition, KGF treatment resulted in higher levels of SP-C on days 2 and 8 while lowering them on day 4, higher levels of AQP5 on day 4 while lowering them on day 8, and higher levels of TTF-1 on days 2, 6, and 8. Conclusion: KGF treatment promoted proliferation of AECIIs, inhibited cell apoptosis, promoted transdifferentiation of AECIIs, and induced alveolar epithelial type I cells to revert to AECIIs. [ABSTRACT FROM AUTHOR]